Optimizing CIGB-300 intralesional delivery in locally advanced cervical cancer

BACKGROUND: We conducted a phase 1 trial in patients with locally advanced cervical cancer by injecting 0.5 ml of the CK2-antagonist CIGB-300 in two different sites on tumours to assess tumour uptake, safety, pharmacodynamic activity and identify the recommended dose. METHODS: Fourteen patients were...

Descripción completa

Detalles Bibliográficos
Autores principales: Sarduy, M R, García, I, Coca, M A, Perera, A, Torres, L A, Valenzuela, C M, Baladrón, I, Solares, M, Reyes, V, Hernández, I, Perera, Y, Martínez, Y M, Molina, L, González, Y M, Ancízar, J A, Prats, A, González, L, Casacó, C A, Acevedo, B E, López-Saura, P A, Alonso, D F, Gómez, R, Perea-Rodríguez, S E
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2015
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4430720/
https://www.ncbi.nlm.nih.gov/pubmed/25880012
http://dx.doi.org/10.1038/bjc.2015.137

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4430720/
https://www.ncbi.nlm.nih.gov/pubmed/25880012
http://dx.doi.org/10.1038/bjc.2015.137

Ejemplares similares